The imidazoline I2 receptors (I2-IRs) are altered in the brain of Alzheimer’s disease patients and I2-IR ligands may have therapeutic potential as neuroprotective agents. Since structural data for I2-IR remains unknown, the discovery of selective I2-IR ligands is likely to provide valuable tools in defining the pharmacological characterization of these receptors.
We are interested in the pharmacological characterization of a new family of (2-imidazolin-4-yl)phosphonates that displayed high affinity for I2-IRs, and high I2/α2 selectivity. In vivo studies in the female SAMP8 mice showed that treatments with two of our previously reported I2-IR ligands produce beneficial effects in behavior and cognition.
Changes in molecular pathways demonstrate the neuroprotective role for these new I2-IR ligands, being promising therapeutic agents in brain disorders and age-related neurodegenerative diseases.
New imidazoline I2 receptor ligands
Diagnostics with Modern Chemical Probes
Generation of functional probes by modern chemistry such as CH activation for modified tryptophan peptides and the preparation of fluorescent…
+ info
Neurodegeneration in ageing and neurodegenerative diseases
We focus our research in the study of the molecular mechanisms involved in behavioral abnormalities and cognitive decline, by using…
+ info
Design, synthesis and evaluation of new polycyclic inhibitors of the M2 channel of the influenza A virus.
Amantadine and rimantadine have been in clinical use as anti-influenza A virus agents for decades. The mechanism of action of…
+ infoNew imidazoline I2 receptor ligands
The imidazoline I2 receptors (I2-IRs) are altered in the brain of Alzheimer’s disease patients and I2-IR ligands may have therapeutic…
+ info